Levine, Lauren S.
Mahuron, Kelly M.
Tsai, Katy K.
Wu, Clinton
Mattis, Daiva M.
Pauli, Mariela L.
Oglesby, Arielle
Lee, James C.
Spitzer, Matthew H.
Krummel, Matthew F.
Algazi, Alain P.
Rosenblum, Michael D.
Alvarado, Michael
Daud, Adil I. http://orcid.org/0000-0002-6617-8421
Funding for this research was provided by:
Roche
Xencor
Sitryx Bio
AbbVie
Amgen
Array BioPharma
Exelixis
Novartis
Pionyr Immunotherapeutics
National Institute of Diabetes and Digestive and Kidney Diseases (NIH T32 training grant in Gastrointestinal Surgery)
Conquer Cancer Foundation (Young Investigator Award CA-0122026)
Burroughs Wellcome Fund (Burroughs Wellcome CAMS-1010934)
Genentech Foundation for Biomedical Sciences
Amoroso and Cook Fund
Trex Bio
Celgene
MedImmune
Parker Institute for Cancer Immunotherapy
Celldex Therapeutics
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08-AR062064, NIH DP2-AR068130, R21-AR066821)
Article History
Received: 23 February 2020
First Online: 2 June 2020
Disclosures
: Alain P. Algazi discloses institutional research funding from Novartis, Merck, BMS OncoSec, Acerta, AstraZeneca, MedImmune, Tessa, Celldex, and Celgene; consulting with stock options for Oncosec and Valitor; paid advisory board positions for Array and Regeneron; and an unpaid advisory role with Sensei Biotherapeutics. Adil I. Daud discloses research funding from the Amoroso and Cook fund, Parker Institute for Cancer Immunotherapy, Novartis, Merck, BMS, Incyte, AbbVie, OncoSec, Xencor, Pfizer, Roche/Genentech, and Exelixis; Advisory Board participation from Amgen, Array, and Roche/Genentech; and stock ownership in Trex Bio and Pionyr Immunotherapeutics. Matthew F. Krummel is the founder and board member of Pionyr Immunotherapeutics. Lauren S. Levine has received research funding from the Conquer Cancer Foundation CA-0122026. Kelly M. Mahuron received support by the NIH T32 training grant in Gastrointestinal Surgery T32DK007573. Michael D. Rosenblum is a consultant with equity ownership for Trex Bio, holds equity in Sitryx Bio, and has received funding on grants NIH DP2-AR068130, K08-AR062064, AR066821 Burroughs Wellcome CAMS-1010934. Matthew H. Spitzer discloses research funding from Genentech/Roche, Pfizer, Valitor Inc., and Bristol-Myers Squibb, and is a paid consultant for Five Prime Therapeutics, Ono Pharmaceutical, and January, Inc. Katy K. Tsai discloses institutional research funding from BMS, Parker Institute for Cancer Immunotherapy, Oncosec, and Regeneron. The remaining authors have no conflicts of interest.